Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 4, 2015
Reporting Period: Second quarter ended June 30, 2015
This filing serves as a notification that the Company issued a press release regarding its financial results for the second quarter of 2015. The detailed results are contained in Exhibit 99.1, which is incorporated by reference but not included in the text of this 8-K.
Key Financial Metrics
The provided text does not contain specific numerical data for revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being available in the attached press release (Exhibit 99.1) and the upcoming conference call.
Material Changes
No material changes or comparative financial data are disclosed within the body of this 8-K filing. The document solely announces the availability of the Q2 2015 results.
Guidance, Outlook, and Risks
- Conference Call: Management scheduled a conference call for August 5, 2015, at 9:00 a.m. Eastern Time to present the financial results. A live webcast was available via the Company's website.
- Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions. These are subject to risks and uncertainties, including those detailed in the "Risk Factors" section of the Company's 2014 Form 10-K.
- Legal Disclaimer: Information furnished in Item 2.02 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific Q2 2015 revenue and net loss figures.
- Access the archived webcast or listen to the conference call recording for management's commentary on the results.
- Consult the 2014 Form 10-K (filed March 12, 2015) for a comprehensive list of risk factors affecting forward-looking statements.
- Verify the Company's cash position and burn rate, as these are critical metrics for a pharmaceutical company not explicitly detailed in this summary text.